Core Insights - PharmAla Biotech Holdings Inc. has successfully shipped its LaNeo™ MDMA to Johns Hopkins University, marking a significant advancement in MDMA research in the United States [1][2] - The CEO of PharmAla emphasizes the importance of this delivery for clinical trials, which have faced challenges in sourcing investigational medical products [2] - LaNeo™ MDMA is now approved for use in the continental US and is already utilized in clinical trials globally [2] Company Overview - PharmAla Biotech is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, with a dual aim of alleviating the backlog of clinical-grade MDMA and developing novel drugs [4] - The company is currently the only provider of clinical-grade MDMA for patient treatments outside of clinical trials [4] - PharmAla's research unit has completed proof-of-concept research for several drug candidates, including ALA-002, its lead candidate [4] Financial Activities - The company has settled $150,000 in debt by issuing 1,666,667 common shares at a deemed price of $0.09 per share [3]